Mainz Biomed (NASDAQ:MYNZ) Stock Price Up 0.7% – Time to Buy?

Mainz Biomed NV (NASDAQ:MYNZ)’s stock price was up 0.7% on Thursday . The company traded as high as $0.4898 and last traded at $0.4770. Approximately 60,899 shares were traded during trading, a decline of 93% from the average daily volume of 832,986 shares. The stock had previously closed at $0.4738.

Analyst Upgrades and Downgrades

MYNZ has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Mainz Biomed to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Mainz Biomed in a research report on Monday, December 22nd. Finally, Maxim Group downgraded shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

Mainz Biomed Trading Up 0.7%

The firm has a market capitalization of $4.32 million, a price-to-earnings ratio of -0.01 and a beta of 0.31. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.52 and a quick ratio of 0.43. The firm’s 50-day simple moving average is $0.81 and its 200 day simple moving average is $1.15.

Hedge Funds Weigh In On Mainz Biomed

A number of institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC lifted its position in shares of Mainz Biomed by 200.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after buying an additional 20,000 shares during the last quarter. Cerity Partners LLC acquired a new stake in Mainz Biomed in the fourth quarter valued at about $183,000. Finally, Armistice Capital LLC boosted its stake in Mainz Biomed by 45.0% in the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock valued at $402,000 after buying an additional 88,400 shares in the last quarter.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.